首页 › 基金 › Pivotal bioVenture Partners Investment Advisor LLC › OCS

Pivotal bioVenture Partners Investment Advisor LLC 对 OCS 的持仓历史

OCULIS HOLDING AG · 医疗保健

Pivotal bioVenture Partners Investment Advisor LLC 在 Q3 2026 的 13F 申报中披露持有 OCS(OCULIS HOLDING AG)1,658,907 股,市值约 US$15.5M,约占其申报组合的 6.31%,在其申报持仓中市值排名第 7 位。 Pivotal bioVenture Partners Investment Advisor LLC 最近 13 个申报季度中有 13 个季度披露了 OCS 持仓,最早可追溯至 Q3 2023。

最新持仓 (Q3 2026)1.66M 股
申报持仓市值$15.49M
组合权重6.31%
首次申报Q3 2023
最近变动增持
更新于2026-11-14

最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR

Pivotal bioVenture Partners Investment Advisor LLC 对 OCS 的持仓演变

Pivotal bioVenture Partners Investment Advisor LLC 于 Q3 2023 首次披露 OCS 持仓:2,218,754 股(约 US$24.4M)。 该持仓在 Q4 2025 达到峰值 2,288,658 股,市值约 US$45.7M。 在 13 次申报中,Pivotal bioVenture Partners Investment Advisor LLC 3 次增持、5 次减持、4 次保持不变。 最近一期申报(Q3 2026)显示持股 1,658,907 股、市值约 US$15.5M,环比增持 152,657 股。。 持仓曾出现大幅变动:Q1 2025 增持约 32% (随后一个季度股价上涨 2%)、Q1 2026 减持约 27% (随后一个季度股价下跌 48%)。

逐季持仓明细

季度股数金额变化
Q3 2023 2.22M $24.41M 新进
Q4 2023 1.89M $21.21M 减持
Q1 2024 1.60M $19.23M 减持
Q2 2024 1.60M $19.07M 持有
Q3 2024 1.60M $19.57M 持有
Q4 2024 1.74M $29.54M 增持
Q1 2025 2.30M $43.78M 增持
Q2 2025 2.30M $44.66M 持有
Q3 2025 2.30M $40.45M 持有
Q4 2025 2.29M $45.70M 减持
Q1 2026 1.68M $44.68M 减持
Q2 2026 1.51M $20.89M 减持
Q3 2026 1.66M $15.49M 增持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 OCS 与 13F 数据

OCS(OCULIS HOLDING AG)属于医疗保健行业。我们追踪的基金中还有 66 只申报持有 OCS,申报仓位最大的包括:EQT Fund Management S.a r.l. (US$64.9M), Gildi - lifeyrissjodur (US$64.3M), Saturn V Capital Management LP (US$9.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 OCS 的基金

查看 OCS 的全部基金持有人 →

常见问题

How long has Pivotal bioVenture Partners Investment Advisor LLC held OCS?

Pivotal bioVenture Partners Investment Advisor LLC has disclosed OCS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Pivotal bioVenture Partners Investment Advisor LLC's current position in OCS?

As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 1.66M shares of OCS (OCULIS HOLDING AG), valued at $15.49M, representing 6.31% of its reported portfolio and ranking #7.

Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling OCS?

In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC increased its position in OCS. The position peaked in Q4 2025 at 2.29M shares.

Which other funds hold OCS?

Other major institutional holders of OCS include EQT Fund Management S.a r.l., Gildi - lifeyrissjodur, Saturn V Capital Management LP, among 66 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.